Editorial: Influence of potential diagnostic biomarkers in lung cancer

Le résumé fourni par la source

Non small cell lung cancer, SCLC -small cell lung cancer, prognostic biomarker Editorial on the Research Topic Influence of potential diagnostic biomarkers in lung cancerLung cancer remains the leading cause of cancer-related death worldwide (1).However, in recent years, there have been significant advancements in patient prognosis, primarily due to the discovery of a variety of therapeutic options.These include targeted therapies such as tyrosine kinase inhibitors (TKIs), immunotherapy with immune checkpoint inhibitors (ICIs), treatment combinations, and new treatment schedules for conventional therapies (2).The successful implementation of these treatment options is closely related to the precise molecular and cellular characterization of tumor samples.By identifying specific molecular aberrations, such as EGFR, ALK, BRAF mutations, or MET amplifications, oncologists can tailor treatments to target the underlying genetic alterations (3).Additionally, understanding the histological types, disease stages, metastatic spread, and PDL-1 levels plays a crucial role in devising personalized treatment plans.However, despite the advancements in treatment options, the prognosis for a significant fraction of lung cancer patients remains poor.This can be attributed to the insufficiency of available methods and or biomarkers to accurately diagnose, stratify, and predict patient responses to the available treatment options (2).Addressing these limitations in prognostic accuracy is crucial, as it can lead to improved screening efficiency, better risk stratification, and the ability to tailor treatments more effectively.Consequently, this has the potential to reduce health disparities among patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.